Company Overview and News

0
Supreme Petrochem Limited - Updates

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Updates

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Outcome of Board Meeting

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - AGM/Book Closure

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Dividend

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Outcome of Board Meeting

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Dividend

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

0
Supreme Petrochem Limited - Financial Result Updates

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUPPETRO 500405

28
21
Market Live: Sensex holds early gains; RIL gains 2% after Feb telecom data

2018-04-24 moneycontrol
11:59 am Crude Update: International oil prices hit their highest levels since late 2014, pushed up by expectations of renewed US sanctions against Iran and as OPEC continues withholding supplies amid strong demand.
500407 PIONDIST BHRYY JUBILANT 500325 RELIANCE 500405 TCHQY ICLQY 530019 BHRQY 532755 532710 THOMASCOOK 500470 532187 534816 RIGD 500477 INFRATEL SADBHAV BHARTIARTL RLNIY ASHOKLEY 500413 INDUSINDBK SWARAJENG 531879 533023 532822 AKLD TECHM ZENSARTECH 532454 504067 SUPPETRO TTST TATASTEEL TATLY IDEA WABCOINDIA DCMSHRIRAM AKLS 523367

17
Market Live: Sensex holds early gains; IT stocks decline, oil banks gain

2018-04-24 moneycontrol
10:50 am Recommendation: Reliance Securities said acquisition of Bharat Financial Inclusion has placed IndusInd Bank in a sweet spot. "With access to best-in-class microfinance business network along with scale and profitability, we envisage significant upside potential in terms of loan growth, fee income generation and CASA mobilisation, going forward."
500407 PIONDIST BHRYY JUBILANT 500325 RELIANCE 500405 TCHQY 530019 BHRQY 532755 532710 THOMASCOOK 500470 532187 534816 RIGD 500477 INFRATEL SADBHAV BHARTIARTL RLNIY ASHOKLEY 500413 INDUSINDBK SWARAJENG 531879 533023 AKLD TECHM ZENSARTECH 532454 504067 SUPPETRO TTST TATASTEEL TATLY WABCOINDIA DCMSHRIRAM AKLS 523367

15
Market Live: Sensex up 100 pts, Nifty nears 10,600 on Asian cues; metals melt

2018-04-24 moneycontrol
10:05 am Jubilant Life Sciences in focus: Jubilant Life Sciences share price gained 3.5 percent after the company has issued commercial papers (CPs) of Rs 75 crore on April 23.
500407 PIONDIST BHRYY JUBILANT 500325 RELIANCE 500405 TCHQY 530019 BHRQY 532755 532710 THOMASCOOK 500470 534816 RIGD 500477 INFRATEL SADBHAV BHARTIARTL RLNIY ASHOKLEY 500413 SWARAJENG 531879 AKLD TECHM ZENSARTECH 532454 504067 SUPPETRO TTST TATASTEEL TATLY DCMSHRIRAM AKLS 523367

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...